THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2025 and business updates. Tabelecleucel (tab-cel® or Ebvallo™) for Post-Transplant Lymphoproliferative Disease (PTLD) The U.S. Food and Drug Administration (FDA) has
Related Questions
What are the key financial metrics from the Q2 2025 results (revenue, net loss, cash burn) and how do they compare to prior quarters and consensus estimates?
What is the current cash runway and when will the next financing be required, if at all?
What is the status of FDA review for Tabelecleucel (tab-cel/Ebvallo) and the expected timeline for approval or any upcoming FDA milestones?
What are the projected commercial launch timelines for Tabelecleucel in PTLD and any potential label expansions?
How does the potential market size for PTLD and other EBV‑related indications compare to competitors' pipelines?
What are the anticipated peak sales and market share assumptions for Tabelecleucel if approved?
What are the key milestones (clinical, regulatory, commercial) expected in the next 12‑18 months for the company's pipeline?
What is the current status of the company's other pipeline candidates (e.g., autoimmune disease programs) and their expected timelines?
How does the company's allogeneic EBV T‑cell platform compare to other allogeneic or CAR‑T platforms in terms of efficacy, safety, and cost?
What are the potential regulatory risks or uncertainties that could affect the approval or commercialization of Tabelecleucel?
Are there any partnership, licensing, or collaboration agreements that could impact future revenue or dilution?
What is the share dilution impact from any recent or anticipated stock issuances or convertible securities?
How does Atara's valuation (price‑to‑sales, price‑to‑cash‑flow, etc.) compare with peer companies in the T‑cell immunotherapy space?
What is the expected impact on the stock price from the Q2 results and the FDA update, and what are the analyst consensus revisions?
What are the company's plans for commercialization (salesforce, distribution, pricing strategy) if Tabelecleucel receives approval?
What are the company's cost structure and gross margin expectations for the commercialized product?
How does the company's R&D spending trend relate to its pipeline development and cash burn?
What is the timeline and expected cost for the next Phase 2/3 trial for Tabelecel?
What are the potential reimbursement and payer landscape for Tabelecel in the U.S. and internationally?
What are the company's plans for international expansion or regulatory filings outside the U.S.?